It's a health challenge our scientists are relentlessly working to
solve—preventing or delaying the onset of type 1 diabetes.
With 5-10% of people with diabetes having
type 1, it's critical now more than ever for the right
innovations and expertise to converge to help find a solution.
At Novo Nordisk, we're investing significant resources into
improving our understanding of type 1 diabetes. With a long-held
company aspiration to drive change to defeat
diabetes – our research ranges from finding a cure to identifying
Our research team led by Dr. Johnna Wesley in Seattle, WA, is
exploring ways we can delay or possibly prevent the onset of this disease.